Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rank in Stocks
#3774
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Share Price
$4.87
Market Cap
$4.36B
Change (1 day)
-5.47%
Change (1 year)
-15.62%
Country
CN
Trade Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Category
Healthcare
Operating Margin for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Operating Margin as of October 2026 TTM: 75.93%
According to Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd latest financial reports and stock price the company's current Operating Margin (TTM) is 75.93%. At the end of 2024 the company had an Operating Margin of 60.87%.
Operating Margin history for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd from 2006 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 75.93% | 0.98% |
| 2025 | 75.19% | 23.53% |
| 2024 | 60.87% | 93.98% |
| 2023 | 31.38% | 600.45% |
| 2022 | 4.48% | -195.32% |
| 2021 | -4.70% | -84.84% |
| 2020 | -31.00% | -240.46% |
| 2019 | 22.07% | -40.19% |
| 2018 | 36.90% | -7.63% |
| 2017 | 39.95% | 45.80% |
| 2016 | 27.40% | 28.58% |
| 2015 | 21.31% | 16.51% |
| 2014 | 18.29% | -50.81% |
| 2013 | 37.18% | -2.87% |
| 2012 | 38.28% | -0.67% |
| 2011 | 38.54% | -8.28% |
| 2010 | 42.02% | 17.80% |
| 2009 | 35.67% | 26.04% |
| 2008 | 28.30% | 1,216.28% |
| 2007 | 2.15% | -102.00% |
| 2006 | -107.42% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.49% |
US
|
|
| -149.01% | -101.96% |
US
|
|
| 25.57% | -99.66% |
AU
|
|
| 31.23% | -99.59% |
BE
|
|
| 28.81% | -99.62% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.